Skip to main content
SpringerLink
Log in

Evolution of biomarker qualification at the health authorities

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

By streamlining the qualification process for biomarkers, coordinated protocols recently implemented at the different regulatory agencies can facilitate progress and provide impetus to novel biomarker discovery and validation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. European Agency for the Evaluation of Medical Products. Public Statement: EU–US FDA Bilateral Agreement (EMEA, London, UK, 2003; accessed 8 September 2009). http://www.emea.europa.eu/pdfs/general/direct/pr/2447803en.pdf

  2. The Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions (FDA, Rockville, Maryland, USA, March 2005; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079849.pdf

  3. European Agency for the Evaluation of Medical Products. Medicines and Emerging Science (EMEA, London, UK, accessed 8 September 2009) http://www.emea.europa.eu/htms/human/mes/emergingtechnologies.htm

  4. The Food and Drug Administration. Fed. Reg. 69, 48876–48877 (2004). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18360.htm

  5. The European Medicines Agency. EMEA/CHMP/PGxWP/20227/04 Guideline on Pharmacognetics Briefing Meetings (EMEA, London, UK, 2004; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf

  6. Uyama, Y. Nippon Yakurigaku Zasshi 126, 432–435 (2005).

    PubMed  Google Scholar 

  7. The Food and Drug Administration. Critical Path Initiative (FDA, Rockville, Maryland, USA, (2004) http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm

  8. The European Medicines Agency. The European Medicines Agency Road Map to 2015: Preparing the Ground for the Future (EMEA, London, UK, 2010; 8 September 2009). http://www.emea.europa.eu/htms/general/direct/roadmap/roadmapintro.htm

  9. The European Medicines Agency. Innovative Drug Development Approaches (EMEA/127318/2007)—Final Report of the EMEA/CHMP Think-Tank on Innovative Drug Development (EMEA, London, UK, 2007; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/itf/12731807en.pdf

  10. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology. 245, 219–223 (2008).

    Article  CAS  Google Scholar 

  11. Hunter, A.J. Drug Discov. Today. 13, 371–373 (2008).

    Article  Google Scholar 

  12. The European Medicines Agency. Final Report on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers (EMEA, London, UK, May 2008; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/25088508en.pdf

  13. Altar, C.A. et al. Clin. Pharmacol. Ther. 83, 368–371 (2008).

    Article  CAS  Google Scholar 

  14. Lathia, C.D. et al. Clin. Pharmacol. Ther. 86, 32–43 (2009).

    Article  CAS  Google Scholar 

  15. The Food and Drug Administration. E16 Genomic Biomarkers Related to Drug Response: Context, Structure, and Format of Qualification Submissions (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174433.pdf

  16. The Food and Drug Administration. Fed. Reg. 69, 42060–42061 (2004; accessed 8 September 2009). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-15935.htm

  17. The Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.

  18. The European Medicines Agency. Guidance Document on the Qualification of Novel Methodologies for Drug Development (EMEA, London, UK, January 2009; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/7289408en.pdf

Download references

Author information

Author notes

  1. Marisa Papaluca is at The European Medicines Agency, London, UK.

Authors and Affiliations

  1. Federico Goodsaid is at the Food and Drug Administration, Silver Spring, Maryland, USA, and,

    Federico Goodsaid & Marisa Papaluca

Authors
  1. Federico Goodsaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marisa Papaluca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Federico Goodsaid or Marisa Papaluca.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goodsaid, F., Papaluca, M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol 28, 441–443 (2010). https://doi.org/10.1038/nbt0510-441

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0510-441

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation